Former Roche man Guido Magni joins Versant

pharmafile | March 22, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Versant, appointment, investment firm 

Dr Guido Magni is joining US-based firm Versant Ventures as a venture partner to further strengthen the firm’s investment team and expand its biotechnology footprint across the world.  

He will invest in innovative startups as part of Versant’s strategy to fund first-in-class healthcare technologies, and formerly worked as a senior executive at Roche.

Dr Magni was previously a managing director of EuroVentures, a Versant biotechnology incubator, and there played an instrumental role in Versant’s investment in Okairos, a clinical stage genetic vaccine company spun out from Merck.

Before EuroVentures, Dr Magni was the global head of medical sciences at Roche for 12 years. There he oversaw the development strategy of more than a dozen successfully launched products during his tenure.

Advertisement

He will be based in Basel, as was EuroVentures. Basel is the home of Roche and Novartis, with whom Dr Magni has worked extensively during his career.

In addition to these pharma companies, Dr Magni also will work with entrepreneurs and academicians and focus on new investment opportunities elsewhere in Europe and the world.

Related Content

David Wheadon appointed to board of directors at Seaport Therapeutics

This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

sarah_mcdonald

Myeloma UK reveals new Director of Research appointment

UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …

white_and_ford

Abbott CEO to step down after 21 years

After more than two decades at the head of the company, it has emerged that …

The Gateway to Local Adoption Series

Latest content